Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02CFE
|
|||
| Former ID |
DNC001002
|
|||
| Drug Name |
NC-2100
|
|||
| Synonyms |
NC-2100; nc2100; SCHEMBL377641; NC 2100; 179068-64-5; 2,4-Thiazolidinedione, 5-((7-(phenylmethoxy)-3-quinolinyl)methyl)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H16N2O3S
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)COC2=CC3=NC=C(C=C3C=C2)CC4C(=O)NC(=O)S4
|
|||
| InChI |
1S/C20H16N2O3S/c23-19-18(26-20(24)22-19)9-14-8-15-6-7-16(10-17(15)21-11-14)25-12-13-4-2-1-3-5-13/h1-8,10-11,18H,9,12H2,(H,22,23,24)
|
|||
| InChIKey |
AZKFGOQRYCSQPK-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 179068-64-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mitochondrial uncoupling protein 1 (UCP1) | Target Info | Inducer | [1] |
| Mitochondrial uncoupling protein 2 (UCP2) | Target Info | Inducer | [1] | |
| KEGG Pathway | PPAR signaling pathway | |||
| Huntington's disease | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | FOXA2 and FOXA3 transcription factor networks | |||
| WikiPathways | Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | |||
| Electron Transport Chain | ||||
| Adipogenesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice. Diabetes. 2000 May;49(5):759-67. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.